MCID: BLD032
MIFTS: 34

Bile Duct Adenocarcinoma

Categories: Cancer diseases, Gastrointestinal diseases, Liver diseases

Aliases & Classifications for Bile Duct Adenocarcinoma

MalaCards integrated aliases for Bile Duct Adenocarcinoma:

Name: Bile Duct Adenocarcinoma 12 15 70

Classifications:



External Ids:

Disease Ontology 12 DOID:4896
NCIt 50 C27813
SNOMED-CT 67 70179006
UMLS 70 C1370800

Summaries for Bile Duct Adenocarcinoma

Disease Ontology : 12 A bile duct carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Bile Duct Adenocarcinoma is related to intrahepatic cholangiocarcinoma and bile duct cysts. An important gene associated with Bile Duct Adenocarcinoma is S100A4 (S100 Calcium Binding Protein A4), and among its related pathways/superpathways are MicroRNAs in cancer and Cell Differentiation - Index. The drugs Sorafenib and Erlotinib Hydrochloride have been mentioned in the context of this disorder. Affiliated tissues include liver, bone and thyroid.

Related Diseases for Bile Duct Adenocarcinoma

Diseases related to Bile Duct Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 228)
# Related Disease Score Top Affiliating Genes
1 intrahepatic cholangiocarcinoma 30.9 MIR424 KRT19 AFP
2 bile duct cysts 30.5 KRT19 AFP
3 cholangitis, primary sclerosing 30.5 MIR199A1 KRT19 AFP
4 bile duct cancer 30.3 MIR9-1 MIR424 MIR31 MIR21 MIR199A1 MIR17
5 extrahepatic bile duct adenocarcinoma 11.4
6 papillary extrahepatic bile duct adenocarcinoma 11.2
7 malignant iris melanoma 10.5 S100A1 MIR106A
8 pericardial mesothelioma 10.5 S100A1 MIR17 KRT19
9 esophagus adenocarcinoma 10.5 MIR21 MIR199A1 MIR145
10 fetal alcohol syndrome 10.5 MIR9-1 KDM4C H2AC18
11 gallbladder leiomyosarcoma 10.5 KRT19 AFP
12 oropharynx cancer 10.5 MIR9-1 MIR199A1 H2AC18
13 cerebral arterial disease 10.5 MIR199A1 MIR145 MIR125A
14 thymus lipoma 10.5 KRT19 AFP
15 immune system organ benign neoplasm 10.5 KRT19 AFP
16 melanoma in congenital melanocytic nevus 10.5 S100A1 MIR199A1 KDM4C H2AC18
17 hereditary lymphedema 10.5 MIR150 KDM4C H2AC18
18 extrinsic cardiomyopathy 10.5 MIR21 MIR199A1 H2AC18
19 hereditary lymphedema i 10.5 MIR150 KDM4C H2AC18
20 mature t-cell and nk-cell lymphoma 10.5 MIR199A1 MIR17 KDM4C H2AC18
21 lipomatosis, multiple symmetric 10.5 MIR483 MIR140 MIR125A
22 chromosome 16p13.3 deletion syndrome, proximal 10.5 MIR9-1 KDM4C H2AC18
23 cervix small cell carcinoma 10.5 MIR199A1 MIR145
24 ovarian serous carcinoma 10.5 MIR21 MIR199A1 MIR145 MIR125A
25 renal pelvis adenocarcinoma 10.5 KRT19 AFP
26 heart septal defect 10.5 MIR199A1 MIR17 H2AC18
27 suppression of tumorigenicity 12 10.5 MIR199A1 MIR145 KDM4C H2AC18
28 muscle cancer 10.5 MIR9-1 MIR199A1 H2AC18
29 paratesticular lipoma 10.5 KRT19 AFP
30 oral cancer 10.5 MIR31 MIR21 KRT19
31 pleural disease 10.5 MIR199A1 MIR17 MIR125A H2AC18
32 lower lip cancer 10.5 MIR31 MIR21
33 lipoma of spermatic cord 10.5 KRT19 AFP
34 fetal alcohol spectrum disorder 10.5 MIR9-1 MIR140 KDM4C H2AC18
35 lipid storage disease 10.5 MIR21 MIR199A1 MIR144 H2AC18
36 cardiovascular organ benign neoplasm 10.5 KDM4C H2AC18 AFP
37 leiomyoma, uterine 10.5 MIR21 MIR150 MIR144
38 uveal disease 10.5 MIR9-1 MIR199A1 MIR125A H2AC18
39 testicular disease 10.5 MIR199A1 KDM4C H2AC18 AFP
40 intestinal benign neoplasm 10.5 MIR21 MIR199A1 MIR17 MIR145 H2AC18
41 pre-malignant neoplasm 10.5 MIR17 KRT19 H2AC18
42 disorder of sexual development 10.5 MIR483 H2AC18 AFP
43 germ cell and embryonal cancer 10.4 MIR9-1 KDM4C H2AC18 AFP
44 larynx cancer 10.4 MIR31 MIR21 MIR17 MIR125A
45 primary bacterial infectious disease 10.4 MIR21 MIR144 MIR125A H2AC18
46 retinal vascular disease 10.4 MIR21 MIR199A1 MIR17 MIR144 H2AC18
47 infratentorial cancer 10.4 MIR9-1 MIR199A1 MIR17 KDM4C H2AC18
48 intrinsic cardiomyopathy 10.4 MIR21 MIR199A1 H2AC18
49 autoimmune disease of gastrointestinal tract 10.4 MIR199A1 MIR150 H2AC18
50 sclerosing hepatic carcinoma 10.4 KRT19 AFP

Graphical network of the top 20 diseases related to Bile Duct Adenocarcinoma:



Diseases related to Bile Duct Adenocarcinoma

Symptoms & Phenotypes for Bile Duct Adenocarcinoma

Drugs & Therapeutics for Bile Duct Adenocarcinoma

Drugs for Bile Duct Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 6)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
2
Erlotinib Hydrochloride Phase 2 183319-69-9 176871
3 Protein Kinase Inhibitors Phase 2
4
Durvalumab Approved, Investigational Phase 1 1428935-60-7
5
Guadecitabine Investigational Phase 1 929901-49-5
6 Antineoplastic Agents, Immunological Phase 1

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Phase II Study of Sorafenib (NSC-724772) and Erlotinib (NSC-718781) in Patients With Advanced Gallbladder Carcinoma or Cholangiocarcinoma Completed NCT01093222 Phase 2 Erlotinib Hydrochloride;Sorafenib Tosylate
2 A Phase Ib Study of Guadecitabine (SGI-110) and Durvalumab (MEDI 4736) in Patients With Advanced Hepatocellular Carcinoma, Pancreatic Adenocarcinoma, and Cholangiocarcinoma/Gallbladder Cancer Recruiting NCT03257761 Phase 1 Guadecitabine
3 A Phase I Clinical Trial of Capecitabine and SIR-Spheres® Y-90-Radioembolization in Patients With Advanced Intrahepatic Cholangiocarcinoma Withdrawn NCT03117855 Phase 1 Capecitabine

Search NIH Clinical Center for Bile Duct Adenocarcinoma

Genetic Tests for Bile Duct Adenocarcinoma

Anatomical Context for Bile Duct Adenocarcinoma

MalaCards organs/tissues related to Bile Duct Adenocarcinoma:

40
Liver, Bone, Thyroid, Heart, Skin, Lymph Node, Pancreas

Publications for Bile Duct Adenocarcinoma

Articles related to Bile Duct Adenocarcinoma:

(show top 50) (show all 64)
# Title Authors PMID Year
1
New staining method using methionyl-tRNA synthetase 1 antibody for brushing cytology of bile duct cancer. 61
31874158 2020
2
Hypercalcemia of Malignancy in a Dog Diagnosed With Cholangiocellular Carcinoma. 61
31122681 2019
3
Analysis of intrahepatic sarcomatoid cholangiocarcinoma: Experience from 11 cases within 17 years. 61
30774275 2019
4
[Strategy in management of adjacent organ lesion during laparoscopic pancreaticoduodenectomy]. 61
30032534 2018
5
Lung Metastases from Bile Duct Adenocarcinoma Mimicking Chronic Airway Infection and Causing Diagnostic Difficulty. 61
29279503 2018
6
Primary intrahepatic bile duct adenocarcinoma complicating with nonalcoholic fatty liver disease in an elderly woman: independent risk factor or a mere coincidence? A case report. 61
31938407 2018
7
Intraductal papillary bile duct adenocarcinoma and gastrointestinal stromal tumor in a case of neurofibromatosis type 1. 61
29398874 2018
8
An extremely rare case of distal common bile duct adenocarcinoma in a 65-year-old male patient. 61
29940641 2018
9
Benign Beale Gland Hyperplasia Mimicking Malignant Biliary Obstruction. 61
28892911 2017
10
Bile Duct Adenocarcinoma with Acute on Chronic Pancreatitis: A Rare Complication of Long Standing Choledochal Cyst. 61
28764249 2017
11
Differentiation grade for extrahepatic bile duct adenocarcinoma: Assessed by diffusion-weighted imaging at 3.0-T MR. 61
27776649 2016
12
Laryngeal metastasis from bile duct adenocarcinoma. 61
26614301 2016
13
Prognostic Value of FDG-PET/CT Total Lesion Glycolysis for Patients with Resectable Distal Bile Duct Adenocarcinoma. 61
26637926 2015
14
The utility of villin and mammaglobin in the differential diagnosis between intrahepatic cholangiocarcinoma and breast cancer. 61
25153498 2015
15
High expression of L-type amino acid transporter 1 as a prognostic marker in bile duct adenocarcinomas. 61
24890221 2014
16
Prognostic factors following surgical resection of distal bile duct cancer. 61
24266011 2013
17
Review of the investigation and surgical management of resectable ampullary adenocarcinoma. 61
23458317 2013
18
Hilar cholangiocarcinoma accompanied by pancreaticobiliary maljunction without bile duct dilatation 20 years after cholecystectomy: report of a case. 61
23614928 2013
19
Intracellular localization of mesothelin predicts patient prognosis of extrahepatic bile duct cancer. 61
23064529 2012
20
Common bile duct adenocarcinoma in a patient with situs inversus totalis: report of a rare case. 61
23234596 2012
21
Use of IMP3, S100P, and pVHL immunopanel to aid in the interpretation of bile duct biopsies with atypical histology or suspicious for malignancy. 61
22495381 2012
22
Comparison of three-dimensional negative-contrast CT cholangiopancreatography with three-dimensional MR cholangiopancreatography for the diagnosis of obstructive biliary diseases. 61
21377820 2012
23
Pathologic observations of the duodenum in 615 consecutive duodenal specimens in a single Japanese hospital: II. malignant lesions. 61
22295147 2012
24
Adequate lymph node assessment for extrahepatic bile duct adenocarcinoma. 61
20224368 2010
25
The mesopancreas is the primary site for R1 resection in pancreatic head cancer: relevance for clinical trials. 61
19418067 2010
26
Large-cell neuroendocrine carcinoma of the distal bile duct. 61
26192428 2009
27
Expression of syndecan-1 and E-cadherin is inversely correlated with poor patient's prognosis and recurrent status of extrahepatic bile duct carcinoma. 61
19420730 2009
28
Bile duct adenocarcinoma with minor micropapillary component: a case report. 61
19144165 2009
29
Efficacy and safety of S-1 monotherapy in patients with advanced biliary tract adenocarcinoma: retrospective analysis of 162 patients. 61
19158445 2009
30
Extrahepatic bile duct adenocarcinoma: patients at high-risk for local recurrence treated with surgery and adjuvant chemoradiation have an equivalent overall survival to patients with standard-risk treated with surgery alone. 61
18754070 2008
31
Second surgery after a pancreaticoduodenectomy in patients with periampullary malignancies. 61
18613434 2008
32
Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells. 61
17724801 2007
33
Laparoscopic pancreaticoduodenectomy: technique and outcomes. 61
17660068 2007
34
Radiochemotherapy followed by gemcitabine and capecitabine in extrahepatic bile duct cancer: a phase I/II trial. 61
17148994 2006
35
Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis. 61
16416732 2005
36
A patient undergoing pancreaticoduodenectomy in whom involved common hepatic artery anomalously arising from the superior mesenteric artery was removed and reconstructed. 61
16334799 2005
37
Survival of patients with periampullary carcinoma is predicted by lymph node 8a but not by lymph node 16b1 status. 61
15515111 2004
38
Recurrent disease after microscopically radical (R0) resection of periampullary adenocarcinoma in patients without adjuvant therapy. 61
15531230 2004
39
A fatal overdose of the ergot derivative cabergoline. 61
15485721 2004
40
Outcome of paraaortic node-positive pancreatic head and bile duct adenocarcinoma. 61
15191867 2004
41
Combined adult-to-adult living donor right lobe liver transplantation and pancreatoduodenectomy for distal bile duct adenocarcinoma in a patient with primary sclerosing cholangitis. 61
14585411 2003
42
Establishment and characterization of novel xenograft models of human biliary tract carcinomas. 61
14532968 2003
43
A comparison of pancreaticogastrostomy and pancreaticojejunostomy following pancreaticoduodenectomy. 61
12850681 2003
44
DPC-4 (Smad-4) and K-ras gene mutations in biliary tract epithelium in children with anomalous pancreaticobiliary ductal union. 61
12720172 2003
45
Biliary stones and stenoses: diagnostic value of magnetic resonance cholangiography. 61
16378295 2002
46
Image analysis of Transwell assays in the assessment of invasion by malignant cell lines. 61
12000178 2002
47
Comparison between pancreatoduodenectomy and hepatopancreatoduodenectomy for bile duct cancer. 61
11490856 2001
48
Cholangioscopic findings in bile duct tumors. 61
11060187 2000
49
The role of S100A4 gene encoding an S100-related calcium-binding protein in human bile duct adenocarcinoma cell lines: correlation of S100A4 expression and invasive growth in Matrigel Matrix. 61
11029520 2000
50
Usefulness of cholangioscopy in patients with focal stricture of the intrahepatic duct unrelated to intrahepatic stones. 61
9925699 1999

Variations for Bile Duct Adenocarcinoma

Expression for Bile Duct Adenocarcinoma

Search GEO for disease gene expression data for Bile Duct Adenocarcinoma.

Pathways for Bile Duct Adenocarcinoma

Pathways related to Bile Duct Adenocarcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.77 MIR9-1 MIR483 MIR31 MIR21 MIR199A1 MIR17
2 10.71 MIR9-1 MIR199A1 MIR150
3 10.27 MIR199A1 MIR145

GO Terms for Bile Duct Adenocarcinoma

Cellular components related to Bile Duct Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.4 S100A4 MIR424 MIR31 MIR21 MIR199A1 MIR17
2 extracellular vesicle GO:1903561 9.26 MIR21 MIR17 MIR125A MIR106A

Biological processes related to Bile Duct Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.96 MIR21 MIR144 MIR140 MIR125A KDM4C
2 negative regulation of gene expression GO:0010629 9.85 MIR21 MIR17 MIR144 MIR140 MIR125A
3 negative regulation of angiogenesis GO:0016525 9.73 MIR424 MIR21 MIR145 MIR125A
4 negative regulation of cell migration involved in sprouting angiogenesis GO:0090051 9.67 MIR483 MIR424 MIR199A1
5 negative regulation of cardiac muscle cell apoptotic process GO:0010667 9.65 MIR21 MIR199A1 MIR145
6 negative regulation of cardiac muscle hypertrophy GO:0010614 9.58 MIR21 MIR145
7 negative regulation of low-density lipoprotein particle clearance GO:0010989 9.58 MIR199A1 MIR17
8 positive regulation of sprouting angiogenesis GO:1903672 9.58 S100A1 MIR31 MIR125A
9 negative regulation of cytokine-mediated signaling pathway GO:0001960 9.57 MIR21 MIR125A
10 negative regulation of amyloid precursor protein biosynthetic process GO:0042985 9.56 MIR31 MIR17 MIR144 MIR106A
11 miRNA mediated inhibition of translation GO:0035278 9.56 MIR9-1 MIR483 MIR31 MIR21 MIR17 MIR145
12 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.55 MIR199A1 MIR17
13 negative regulation of vascular endothelial growth factor production GO:1904046 9.55 MIR199A1 MIR17 MIR140 MIR125A MIR106A
14 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.54 MIR31 MIR125A
15 positive regulation of metalloendopeptidase activity GO:1904685 9.52 MIR21 MIR17
16 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.51 MIR21 MIR17
17 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.5 MIR424 MIR21 MIR140
18 gene silencing by miRNA GO:0035195 9.47 MIR9-1 MIR541 MIR483 MIR424 MIR31 MIR21
19 negative regulation of interleukin-16 production GO:0032699 9.37 MIR145 MIR125A

Molecular functions related to Bile Duct Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA 3'-UTR binding GO:0003730 9.65 MIR9-1 MIR424 MIR31 MIR21 MIR17 MIR145
2 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.44 MIR9-1 MIR483 MIR424 MIR31 MIR21 MIR199A1
3 RNA polymerase II complex binding GO:0000993 9.33 MIR145 MIR140 MIR125A

Sources for Bile Duct Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....